Clinical Trials Logo

Filter by:
NCT ID: NCT03249090 Active, not recruiting - Metastatic Cancer Clinical Trials

Electronic Patient Reporting of Symptoms During Cancer Treatment

PRO-TECT
Start date: October 30, 2017
Phase: N/A
Study type: Interventional

The current study is designed to test nationally whether patients' outcomes and utilization of services can be improved through symptom monitoring via patient-reported outcomes between visits.

NCT ID: NCT03248492 Active, not recruiting - Breast Cancer Clinical Trials

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Start date: August 25, 2017
Phase: Phase 2
Study type: Interventional

Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

NCT ID: NCT03247712 Active, not recruiting - Clinical trials for Head and Neck Cancer

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Start date: January 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of neoadjuvant immunoradiotherapy as a safe means of down-staging Head and Neck Squamous Cell Carcinoma (HNSCC) prior to surgical resection.

NCT ID: NCT03247647 Active, not recruiting - Alcohol Abuse Clinical Trials

Personal Values and Mandated Students

Start date: March 13, 2018
Phase: N/A
Study type: Interventional

This study aims to examine the efficacy of an enhanced alcohol intervention among individuals who are mandated to complete an alcohol education activity as part of a university sanction.

NCT ID: NCT03247634 Active, not recruiting - Cancer Prevention Clinical Trials

Getting Ahead for Cancer Control

Start date: December 8, 2017
Phase: N/A
Study type: Interventional

A new, practical program, entitled Getting Ahead in a Just-Gettin'-By World, provides a novel approach to addressing this previously intractable problem. During the progression through the Getting Ahead program, individuals develop an understanding of the hidden rules of economic class and have an opportunity to craft a hopeful future story based on the practical concepts investigated in the modules. Getting Ahead has shown great success in various organizations and communities in multiple sectors, including healthcare, but has not been studied in the context of advancing cancer prevention and control.

NCT ID: NCT03247439 Active, not recruiting - Osteoarthritis Clinical Trials

Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis Compared to LRTI (GRIP 2)

GRIP 2
Start date: December 22, 2017
Phase: N/A
Study type: Interventional

This study will evaluate whether Cartiva is an effective treatment for individuals with osteoarthritis of the first CMC joint in the hand compared to LRTI.

NCT ID: NCT03247088 Active, not recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Start date: July 30, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the best dose of sorafenib when given together with busulfan and fludarabine in treating patients with acute myeloid leukemia that has come back or does not respond to treatment and who are undergoing donor stem cell transplant. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as busulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sorafenib with busulfan and fludarabine may work better in treating patients with recurrent or refractory acute myeloid leukemia.

NCT ID: NCT03246958 Active, not recruiting - Thyroid Cancer Clinical Trials

Nivolumab Plus Ipilimumab in Thyroid Cancer

Start date: October 3, 2017
Phase: Phase 2
Study type: Interventional

This research study is studying nivolumab, an investigational drug, in combination with ipilimumab, also an investigational drug, as a possible treatment for thyroid cancer. The drugs involved in this study are: - Nivolumab (Opdivo™) - Ipilimumab (Yervoy™)

NCT ID: NCT03246529 Active, not recruiting - Multiple Myeloma Clinical Trials

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous TransplantatIon in Subjects With MM

GENESIS
Start date: March 23, 2018
Phase: Phase 3
Study type: Interventional

A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.

NCT ID: NCT03246347 Active, not recruiting - Prostate Cancer Clinical Trials

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Start date: August 23, 2017
Phase: Phase 2
Study type: Interventional

This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer. The purpose of this study is to assess if ADT + docetaxel + enzalutamide is well tolerated and demonstrates improved efficacy compared to ADT + docetaxel.